vs
Esperion Therapeutics, Inc.（ESPR）与弗雷斯特研究公司（FORR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是弗雷斯特研究公司的1.7倍（$168.4M vs $101.1M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -6.5%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 0.5%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
ESPR vs FORR — 直观对比
营收规模更大
ESPR
是对方的1.7倍
$101.1M
营收增速更快
ESPR
高出150.2%
-6.5%
两年增速更快
ESPR
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $101.1M |
| 净利润 | — | $-33.9M |
| 毛利率 | — | 56.7% |
| 营业利润率 | 50.6% | -36.6% |
| 净利率 | — | -33.5% |
| 营收同比 | 143.7% | -6.5% |
| 净利润同比 | — | -7941.4% |
| 每股收益（稀释后） | $0.32 | $-1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRFORR
| Q4 25 | $168.4M | $101.1M | ||
| Q3 25 | $87.3M | $94.3M | ||
| Q2 25 | $82.4M | $111.7M | ||
| Q1 25 | $65.0M | $89.9M | ||
| Q4 24 | $69.1M | $108.0M | ||
| Q3 24 | $51.6M | $102.5M | ||
| Q2 24 | $73.8M | $121.8M | ||
| Q1 24 | $137.7M | $100.1M |
净利润ESPRFORR
| Q4 25 | — | $-33.9M | ||
| Q3 25 | $-31.3M | $-2.1M | ||
| Q2 25 | $-12.7M | $3.9M | ||
| Q1 25 | $-40.5M | $-87.3M | ||
| Q4 24 | — | $432.0K | ||
| Q3 24 | $-29.5M | $-5.8M | ||
| Q2 24 | $-61.9M | $6.3M | ||
| Q1 24 | $61.0M | $-6.7M |
毛利率ESPRFORR
| Q4 25 | — | 56.7% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | 55.5% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 58.8% | ||
| Q3 24 | — | 60.5% | ||
| Q2 24 | — | 57.3% | ||
| Q1 24 | — | 54.9% |
营业利润率ESPRFORR
| Q4 25 | 50.6% | -36.6% | ||
| Q3 25 | -11.4% | 4.7% | ||
| Q2 25 | 8.6% | 6.2% | ||
| Q1 25 | -34.0% | -97.5% | ||
| Q4 24 | -6.4% | -0.5% | ||
| Q3 24 | -31.0% | -0.7% | ||
| Q2 24 | 3.5% | 9.3% | ||
| Q1 24 | 52.5% | -9.3% |
净利率ESPRFORR
| Q4 25 | — | -33.5% | ||
| Q3 25 | -35.9% | -2.3% | ||
| Q2 25 | -15.4% | 3.5% | ||
| Q1 25 | -62.2% | -97.1% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | -57.2% | -5.7% | ||
| Q2 24 | -83.9% | 5.2% | ||
| Q1 24 | 44.3% | -6.7% |
每股收益（稀释后）ESPRFORR
| Q4 25 | $0.32 | $-1.75 | ||
| Q3 25 | $-0.16 | $-0.11 | ||
| Q2 25 | $-0.06 | $0.20 | ||
| Q1 25 | $-0.21 | $-4.62 | ||
| Q4 24 | $-0.14 | $0.02 | ||
| Q3 24 | $-0.15 | $-0.30 | ||
| Q2 24 | $-0.33 | $0.33 | ||
| Q1 24 | $0.34 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $63.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $126.5M |
| 总资产 | $465.9M | $404.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRFORR
| Q4 25 | $167.9M | $63.3M | ||
| Q3 25 | $92.4M | $65.1M | ||
| Q2 25 | $86.1M | $67.8M | ||
| Q1 25 | $114.6M | $75.6M | ||
| Q4 24 | $144.8M | $56.1M | ||
| Q3 24 | $144.7M | $62.8M | ||
| Q2 24 | $189.3M | $58.9M | ||
| Q1 24 | $226.6M | $61.4M |
股东权益ESPRFORR
| Q4 25 | $-302.0M | $126.5M | ||
| Q3 25 | $-451.4M | $157.7M | ||
| Q2 25 | $-433.5M | $159.5M | ||
| Q1 25 | $-426.2M | $147.4M | ||
| Q4 24 | $-388.7M | $229.5M | ||
| Q3 24 | $-370.2M | $234.3M | ||
| Q2 24 | $-344.2M | $237.1M | ||
| Q1 24 | $-294.3M | $230.9M |
总资产ESPRFORR
| Q4 25 | $465.9M | $404.0M | ||
| Q3 25 | $364.0M | $414.2M | ||
| Q2 25 | $347.1M | $436.0M | ||
| Q1 25 | $324.0M | $439.8M | ||
| Q4 24 | $343.8M | $503.9M | ||
| Q3 24 | $314.1M | $505.3M | ||
| Q2 24 | $352.3M | $524.2M | ||
| Q1 24 | $373.1M | $555.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-4.3M |
| 自由现金流率自由现金流/营收 | — | -4.2% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $18.1M |
8季度趋势，按日历期对齐
经营现金流ESPRFORR
| Q4 25 | $45.2M | $-3.2M | ||
| Q3 25 | $-4.3M | $1.2M | ||
| Q2 25 | $-31.4M | $-3.6M | ||
| Q1 25 | $-22.6M | $26.7M | ||
| Q4 24 | $-35.0M | $-1.8M | ||
| Q3 24 | $-35.3M | $264.0K | ||
| Q2 24 | $-7.2M | $-2.9M | ||
| Q1 24 | $53.8M | $611.0K |
自由现金流ESPRFORR
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $524.0K | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $26.1M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | $-35.5M | $-223.0K | ||
| Q2 24 | $-7.3M | $-3.7M | ||
| Q1 24 | $53.8M | $-815.0K |
自由现金流率ESPRFORR
| Q4 25 | — | -4.2% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | -3.8% | ||
| Q1 25 | — | 29.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -68.7% | -0.2% | ||
| Q2 24 | -9.9% | -3.1% | ||
| Q1 24 | 39.0% | -0.8% |
资本支出强度ESPRFORR
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 1.4% |
现金转化率ESPRFORR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
